Mattern Capital Management LLC Buys 1,907 Shares of Becton, Dickinson and Company $BDX

Key Points

• Mattern Capital Management LLC increased its stake in Becton, Dickinson and Company by 5.7%, acquiring an additional 1,907 shares in the 2nd quarter, bringing their total holdings to 35,526 shares valued at approximately $6.12 million.
• Becton, Dickinson and Company reported a 10.4% year-over-year revenue increase, with earnings per share of $3.68 for the last quarter, surpassing the consensus estimate of $3.40.
• The company recently declared a quarterly dividend of $1.04 per share, equivalent to an annual yield of 2.2%, with a payout ratio of 74.82%.

Mattern Capital Management LLC grew its stake in Becton, Dickinson and Company (NYSE:BDX - Free Report) by 5.7% in the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 35,526 shares of the medical instruments supplier's stock after purchasing an additional 1,907 shares during the period. Mattern Capital Management LLC's holdings in Becton, Dickinson and Company were worth $6,119,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Saudi Central Bank purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at $26,000. Smallwood Wealth Investment Management LLC purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at $27,000. Alpine Bank Wealth Management purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at $29,000. Cornerstone Planning Group LLC boosted its holdings in Becton, Dickinson and Company by 341.4% during the 1st quarter. Cornerstone Planning Group LLC now owns 128 shares of the medical instruments supplier's stock valued at $29,000 after acquiring an additional 99 shares during the period. Finally, Kelly Lawrence W & Associates Inc. CA purchased a new position in Becton, Dickinson and Company during the 1st quarter valued at $31,000. 86.97% of the stock is owned by institutional investors.

Insider Buying and Selling at Becton, Dickinson and Company

In related news, Director Claire Fraser sold 917 shares of the business's stock in a transaction on Wednesday, September 10th. The stock was sold at an average price of $187.50, for a total transaction of $171,937.50. Following the transaction, the director directly owned 22,226 shares in the company, valued at $4,167,375. The trade was a 3.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, EVP Michael David Garrison sold 1,185 shares of Becton, Dickinson and Company stock in a transaction dated Friday, July 18th. The stock was sold at an average price of $180.29, for a total value of $213,643.65. Following the sale, the executive vice president directly owned 4,887 shares of the company's stock, valued at approximately $881,077.23. This represents a 19.52% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 3,023 shares of company stock worth $562,036. 0.36% of the stock is owned by company insiders.

Becton, Dickinson and Company Trading Up 0.3%

Shares of NYSE:BDX opened at $191.43 on Friday. Becton, Dickinson and Company has a 12-month low of $163.33 and a 12-month high of $251.99. The business's fifty day simple moving average is $188.87 and its 200-day simple moving average is $187.95. The company has a current ratio of 1.10, a quick ratio of 0.62 and a debt-to-equity ratio of 0.69. The company has a market capitalization of $54.87 billion, a PE ratio of 34.43, a P/E/G ratio of 1.49 and a beta of 0.25.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $3.68 earnings per share for the quarter, topping the consensus estimate of $3.40 by $0.28. Becton, Dickinson and Company had a return on equity of 16.23% and a net margin of 7.51%.The firm had revenue of $5.51 billion for the quarter, compared to the consensus estimate of $5.50 billion. During the same period in the previous year, the business earned $3.50 EPS. The firm's revenue for the quarter was up 10.4% on a year-over-year basis. Becton, Dickinson and Company has set its FY 2025 guidance at 14.300-14.450 EPS. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.43 earnings per share for the current fiscal year.

Becton, Dickinson and Company Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Tuesday, September 30th. Investors of record on Monday, September 8th were paid a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a yield of 2.2%. The ex-dividend date was Monday, September 8th. Becton, Dickinson and Company's payout ratio is 74.82%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Royal Bank Of Canada initiated coverage on Becton, Dickinson and Company in a report on Thursday, September 25th. They set a "sector perform" rating and a $211.00 price objective for the company. Wells Fargo & Company raised their price objective on Becton, Dickinson and Company from $172.00 to $184.00 and gave the stock an "equal weight" rating in a report on Friday, August 8th. Piper Sandler restated a "neutral" rating and set a $200.00 price objective (up from $185.00) on shares of Becton, Dickinson and Company in a report on Friday, August 8th. Morgan Stanley raised their price objective on Becton, Dickinson and Company from $196.00 to $197.00 and gave the stock an "overweight" rating in a report on Monday, August 11th. Finally, Argus raised their price objective on Becton, Dickinson and Company from $220.00 to $230.00 in a report on Monday, September 15th. Three equities research analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company's stock. According to data from MarketBeat, the company has an average rating of "Hold" and an average target price of $205.40.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.